Drug Platform: GEMINI

Gemini is a proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD®) that reduces the damage associated with inflammation by reprogramming the innate immune system to respond to stress (trauma, infection, etc.) in an attenuated manner.

Lead Drug: GEM-AKI

GEM-AKI is designed to help the body’s own immune system calm the harmful inflammation that can damage the kidneys during acute kidney injury (AKI). GEM-AKI is given intravenously (by IV) to patients with moderate to severe AKI, a sudden and dangerous loss of kidney function that often happens during a hospital stay. Having completed early clinical studies, GEM-AKI is now advancing into later-stage development.

Learn More >

Latest News:

GEMINI’S MECHANISM OF ACTION

Gemini Phase 2a Safety & Efficacy Study in AKI

A Randomized, Double-Blind (Sponsor-Unblinded), Placebo-Controlled, Study to Evaluate the Safety, Tolerability, And Efficacy of Gemini in Hospitalized Patients with Severe Stage 2 or Stage 3 Acute Kidney Injury

Advantages:

• Short timeline to data (~1 year vs. 2+ years)

  • Efficacy to include evaluation of clinically relevant endpoints agreed upon with FDA

• Significantly lower cost (~$7M vs. ~$60M to value creation endpoint)